Adults 5 to 12, any sex, with Anxiety. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Perioperative Pediatric Anxiety (Change From Baseline)Primary· (Day 0 + 15 minutes on average from initial baseline) On entering the OR
Modified Yale Preoperative Anxiety Scale (Observational measure of anxiety in five categories (activity, emotional expressivity, state of arousal, vocalization, and use of parents); Total range 0 to 100 with higher scores indicating greater anxiety)
Group
Value
95% CI
Perioperative Virtual Reality Headset
0.0
0.0 – 0.0
Control
5.0
0.0 – 10.0
Perioperative Pediatric Anxiety (Change From Baseline)Primary· (Day 0 + 30 minutes on average from initial baseline) During mask induction
Modified Yale Preoperative Anxiety Scale (Observational measure of anxiety in five categories (activity, emotional expressivity, state of arousal, vocalization, and use of parents); Total range 0 to 100 with higher scores indicating greater anxiety)
Group
Value
95% CI
Perioperative Virtual Reality Headset
0.0
0.0 – 0.0
Control
13.3
5.0 – 26.7
Perioperative Parental Anxiety (Change From Baseline)Secondary· (Day 0 + 45 minutes on average from initial baseline) After mask induction
State-Trait Anxiety Inventory: Self-reported anxiety instrument containing two separate 2-item subscales that measure trait (baseline) and state (situational) anxiety. Total range 20 to 80 with higher scores indicating greater anxiety. The value is a sum of trait and state anxiety.
Group
Value
95% CI
Perioperative Virtual Reality Headset
0
-3 – 3
Control
0
-3 – 3
Induction Compliance ChecklistSecondary· (Day 0 + 30 minutes on average from initial baseline) During mask induction
Induction Compliance Checklist (An observational scale used to describe the compliance of a child during induction of anesthesia, range 0 to 11 with higher scores indicating less compliance)
Group
Value
95% CI
Perioperative Virtual Reality Headset
0
0 – 0
Control
0
0 – 1
Parental SatisfactionSecondary· (Day 0 + 45 minutes on average from initial baseline) After mask induction
21-item parental satisfaction questionnaire after induction of general anesthesia (T3). Parental satisfaction score range: 21-84. Higher scores represent higher satisfaction.
Group
Value
95% CI
Perioperative Virtual Reality Headset
83
76 – 84
Control
80
76 – 83
Anesthesia LengthSecondary· (Day 0 + 120 minutes on average from initial baseline) After exiting the OR
Length of time that patient received anesthesia care.
Group
Value
95% CI
Perioperative Virtual Reality Headset
80
± 91
Control
101
± 119
Surgery LengthSecondary· (Day 0 + 120 minutes on average from initial baseline) After exiting the OR
Length of surgery from procedure start to procedure finish
Group
Value
95% CI
Perioperative Virtual Reality Headset
62
± 85
Control
77
± 106
Pre-medication GivenSecondary· (Day 0 + 30 minutes on average from initial baseline) On induction of anesthesia
Whether patient was given anxiolytic medication prior to induction of general anesthesia
Group
Value
95% CI
Perioperative Virtual Reality Headset
0
Control
0
Perioperative Virtual Reality Headset
34
Control
37
Parent Present for InductionSecondary· (Day 0 + 30 minutes on average from initial baseline) On induction of anesthesia
Whether parent was present in operating room during induction of anesthesia
Group
Value
95% CI
Perioperative Virtual Reality Headset
30
Control
35
Perioperative Virtual Reality Headset
4
Control
2
Sponsor's own description
The goal of this study is to evaluate the use of immersive audiovisual distraction and virtual reality to reduce perioperative anxiety in pediatric patients undergoing surgery at UCSF Benioff Children's Hospital. The study plans to employ virtual reality headsets during induction of anesthesia in pediatric patients for elective surgery in a randomized clinical trial.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or
· Phase 2
· recruiting
NCT07522944 — AI-Guided Relaxation for Hemodialysis Anxiety
· NA
· recruiting
NCT07466875 — Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients
· NA
· recruiting
NCT07425951 — Building Cognitive Behavioural Skills With StoryBooks to Reduce Emotional Difficulties in Kindergarten Years
· NA
· recruiting
NCT07473505 — Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospect
· recruiting
Other University of California, San Francisco trials
Trials by the same sponsor.
NCT05284773 — Screening for Acute Malnutrition
· NA
· withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling
· NA
· not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M
· Phase 1, PHASE2
· not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans
· NA
· not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT)
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 8 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03583450.